Abcam Plc (LON:ABC)‘s stock had its “hold” rating reiterated by investment analysts at Peel Hunt in a report issued on Monday. They currently have a GBX 750 ($9.69) price target on the stock. Peel Hunt’s target price suggests a potential downside of 30.68% from the stock’s current price.
Other analysts have also issued research reports about the stock. Numis Securities Ltd reiterated an “add” rating and set a GBX 1,116 ($14.41) target price on shares of Abcam Plc in a research note on Thursday, July 27th. Berenberg Bank started coverage on shares of Abcam Plc in a research note on Tuesday, June 27th. They set a “buy” rating and a GBX 1,100 ($14.21) target price for the company. Finally, Panmure Gordon reiterated a “sell” rating on shares of Abcam Plc in a research note on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of GBX 914 ($11.80).
Shares of Abcam Plc (LON:ABC) opened at 1098.00 on Monday. The firm’s market cap is GBX 2.22 billion. Abcam Plc has a 52 week low of GBX 759.50 and a 52 week high of GBX 1,100.00. The company’s 50-day moving average is GBX 1,052.08 and its 200-day moving average is GBX 953.19.
Abcam Plc Company Profile
Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company’s purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways.
Receive News & Ratings for Abcam Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam Plc and related companies with MarketBeat.com's FREE daily email newsletter.